SYNCOPE DIAGNOSIS NEEDED.

CHALLENGE ACCEPTED.

ACC/AHA/HRS & ESC Guidelines Recommend ICM in the Evaluation of Unexplained Syncope

Reveal LINQ™ Insertable Cardiac Monitoring
DIAGNOSING UNEXPLAINED SYNCOPE IS CHALLENGING

HALF OF PATIENTS ADMITTED TO THE HOSPITAL FOR SYNCOPE LEAVE WITHOUT A DIAGNOSIS

An average of 251,000 people are hospitalized for syncope every year.²

PATIENTS NEED ANSWERS

3 specialists visited on average³

13 inconclusive tests*³

1 in 4 undergo more than 20 tests⁴

*Median number
GETTING ANSWERS IS URGENT

CARDIAC SYNCOPE IS DEADLY
Cardiac syncope can be a predictor of sudden cardiac death.5

36% suffer significant trauma5

2X increased risk of death6

> 10% mortality rate at six months6

Visit Medtronic.com/Syncope to hear William's story

LIVING WITHOUT A DIAGNOSIS COMPROMISES QUALITY OF LIFE7-9

- 1.4X increased risk of occupational accidents9
- 2X increased risk of loss of employment9

[Bar chart showing percentages of patients suffering from different conditions]

Percent of Patients

<table>
<thead>
<tr>
<th>Condition</th>
<th>Percent</th>
</tr>
</thead>
<tbody>
<tr>
<td>Anxiety/Depression</td>
<td>75%</td>
</tr>
<tr>
<td>Alter Daily Activities</td>
<td>50%</td>
</tr>
<tr>
<td>Restricted Driving</td>
<td>25%</td>
</tr>
<tr>
<td>Change Employment</td>
<td>0%</td>
</tr>
</tbody>
</table>
ACC/AHA/HRS & ESC GUIDELINES
Recommend Cardiac Monitoring with Reveal LINQ™ ICM Early in the Evaluation of Syncope

Reveal LINQ is recommended for patients with infrequent symptoms > 30 days apart

ACC/AHA/HRS 2017 Guidelines Recommendation

<table>
<thead>
<tr>
<th>COR</th>
<th>LOE</th>
<th>RECOMMENDATION</th>
</tr>
</thead>
<tbody>
<tr>
<td>I</td>
<td>NA</td>
<td>If the initial evaluation (history, physical exam, ECG) is unclear and a cardiac cause is suspected, cardiac monitoring is recommended.</td>
</tr>
<tr>
<td>I</td>
<td>C-EO</td>
<td>The choice of a specific cardiac monitor should be determined on the basis of the frequency and nature of syncope events.</td>
</tr>
<tr>
<td>IIa</td>
<td>B-R</td>
<td>To evaluate selected ambulatory patients with syncope of suspected arrhythmic etiology, an ICM can be useful.</td>
</tr>
</tbody>
</table>

COR — Class of Recommendation  
LOE — Level of Evidence

CONTINUE MONITORING.  
GET TO THE ANSWER.  
If initial monitoring is non-diagnostic, keep looking with Reveal LINQ ICM.
ICM is the only ambulatory monitor with a Class I recommendation for syncope

ESC 2018 Guidelines Recommendation

<table>
<thead>
<tr>
<th>COR</th>
<th>LOE</th>
<th>RECOMMENDATION</th>
</tr>
</thead>
<tbody>
<tr>
<td>I</td>
<td>A</td>
<td><strong>UPGRADED:</strong> ICMs upgraded to Class I/Level A recommendation — the strongest level of clinical evidence — for early monitoring in low-risk patients and after workup of high-risk patients.</td>
</tr>
<tr>
<td>IIb</td>
<td>B</td>
<td><strong>NEW:</strong> ICMs added as a Class II/Level B recommendation to diagnose unexplained falls and unconfirmed epilepsy</td>
</tr>
<tr>
<td>IIa</td>
<td>B</td>
<td>ICMs should be considered in patients with suspected or certain reflex syncope presenting with frequent or several syncopal episodes.</td>
</tr>
</tbody>
</table>

**Holter monitor and tilt testing downgraded from Class I to Class II recommendation**

88% of patients who are guideline-eligible for an ICM/ILR are over-tested with other modalities before being offered an ICM/ILR.\(^4\)

Over-testing **increases cost** with no improvement to diagnostic yield.\(^4\)
SUPERIOR DIAGNOSTIC YIELD

Clinical evidence overwhelmingly supports ICM for infrequent syncope

3.6x
more likely to reach a diagnosis with ICM vs. standard of care

2018 ESC Guidelines
Meta-analysis of 5 randomized clinical trials

44%
ICA diagnostic yield

2017 Meta-analysis of 49 studies
4,381 patients

vs. standard of care 5-20%*14-17

*Range for ICM in the same studies was 42-52%.
†84% of the 4,381 patients in the studies were reported to have been tested with a Reveal™ ICM.
PATIENTS WITH LONG-TERM MONITORING GET ANSWERS

EARLIER ICM USE SAVES PATIENTS MONEY

Multiple studies show cost savings with ICM compared to conventional testing due to fewer tests and hospital admissions.14,17-19

REVEAL LINQ ICM BROADLY COVERED

Medicare and private payers cover inpatient and outpatient Reveal LINQ ICM insertions.*

REVEAL LINQ GUIDES TREATMENT DECISIONS

78% of Reveal™ ICM patients with syncope recurrence received a differential diagnosis (PICTURE Study)3

82% of Reveal ICM guided diagnoses led to treatment3

IMPROVED QOL in ICM patients with syncope15,20

SIGNIFICANT REDUCTION in syncope burden with therapies guided by ICM diagnosis21

“Holter monitoring in syncope is inexpensive in terms of setup costs, but expensive in terms of cost per diagnosis.”

–ESC 2018 Syncope Guidelines Task Force11

*Please see coverage guide in Medtronic Reimbursement App for specific coverage information by provider.
PATIENTS PREFER REVEAL LINQ™ ICM
Over External Wearable Monitors22

Continuous, automatic cardiac monitoring and patient-activated symptom marking to correlate symptoms to cardiac rhythms

SIMPLE
Insertion procedure is minimally invasive and brief

CONVENIENT
100% of patients found Reveal LINQ ICM did not limit their activities of daily living22

ULTRA-DISCREET
Not visible in most patients

MRI CONDITIONAL
Safe for MRI at 1.5 and 3.0T even on the same day of insertion*

“[If I’d known about it,] I wouldn’t have requested it — I would have demanded that be done. I was tired of not having any answers.”23,†
–Reveal LINQ Patient

“It . . . was, for me, a peace of mind thing, knowing that, if anything happens, they can capture it.”23,†
–Reveal LINQ Patient

“It’s easier than the portable monitors. . . . I had a very bad accident because I passed out . . . so I was very ready to do anything to make sure that I don’t have another serious accident. . . . I . . . was glad to have a monitor that I don’t have to have around my neck all the time.”23,†
–Reveal LINQ Patient

*Reveal LINQ has been demonstrated to pose no known hazards in a specified MRI environment with specified conditions of use. Please see the Reveal ICM clinician manual or MRI technical manual for more details.

†Patient outcomes may vary.
20% of syncope diagnosed with Reveal ICMs occurred after 2 years\textsuperscript{24}

THE LONGER YOU LOOK, THE MORE YOU FIND

INDUSTRY-LEADING TRURHYTHM\textsuperscript{TM} DETECTION

<table>
<thead>
<tr>
<th></th>
<th>Reduction in false detects\textsuperscript{*}</th>
<th>Relative sensitivity\textsuperscript{*}</th>
</tr>
</thead>
<tbody>
<tr>
<td>BRADY</td>
<td>↓ 95%</td>
<td>98.3%</td>
</tr>
<tr>
<td>PAUSE</td>
<td>↓ 47%</td>
<td>99.4%</td>
</tr>
</tbody>
</table>

\textsuperscript{*}Compared with the Reveal LINQ ICM without TruRhythm Detection

EXCLUSIVE ALGORITHMS

significantly reduce false positives while preserving sensitivity.\textsuperscript{25,26}

INTELLIGENT

Smart Filtering algorithm improves detection accuracy for Brady & Pause.

ACTIONABLE

Streamlined Episodes & Report Updates simplify data review.
References

2. Data obtained from CDC National Hospital Ambulatory Medical Care Survey (NHAMCS) from the years 2008-2014.
18. Davis S, Westby M, Pitcher D, Petkar S. Insertable loop recorders are cost-effective when used to investigate transient loss of consciousness which is either suspected to be arrhythmic or remains unexplained. Europace. March 2012;14(3):402-409.
Indications, Safety, and Warnings

If you are located in the United States, please refer to the brief statement below to review applicable indications, safety, and warning information. See the device manual for detailed information regarding the implant procedure, indications, contraindications, warnings, precautions, and potential complications/adverse events. For further information, please call Medtronic at 763-514-4000 and/or consult the Medtronic website at medtronic.com.

If you are located outside the United States, see the device manual for detailed information regarding the implant procedure, indications, contraindications, warnings, precautions, and potential adverse events. For further information, contact your local Medtronic representative and/or consult the Medtronic website at medtronic.com.

Consult instructions for use at this website. Manuals can be viewed using a current version of any major Internet browser. For best results, use Adobe Acrobat Reader® with the browser.

Important Reminder: This information is intended only for users in markets where Medtronic products and therapies are approved or available for use as indicated within the respective product manuals. Content on specific Medtronic products and therapies is not intended for users in markets that do not have authorization for use.

Reveal LINQ™ LNQ11 Insertable Cardiac Monitor and Patient Assistant

The Reveal LINQ insertable cardiac monitor is an implantable patient-activated and automatically-activated monitoring system that records subcutaneous ECG and is indicated in the following cases:

- Patients with clinical syndromes or situations at increased risk of cardiac arrhythmias
- Patients who experience transient symptoms such as dizziness, palpitation, syncope, and chest pain, that may suggest a cardiac arrhythmia

This device has not specifically been tested for pediatric use.

Patient Assistant

The Patient Assistant is intended for unsupervised patient use away from a hospital or clinic. The Patient Assistant activates the data management feature in the Reveal LINQ insertable cardiac monitor to initiate recording of cardiac event data in the implanted device memory.

Contraindications

There are no known contraindications for the implant of the Reveal LINQ insertable cardiac monitor. However, the patient’s particular medical condition may dictate whether or not a subcutaneous, chronically implanted device can be tolerated.

Warnings and Precautions

Reveal LINQ LNQ11 Insertable Cardiac Monitor

Patients with the Reveal LINQ insertable cardiac monitor should avoid sources of diathermy, high sources of radiation, electrosurgical cautery, external defibrillation, lithotripsy, therapeutic ultrasound, and radiofrequency ablation to avoid electrical reset of the device, and/or inappropriate sensing as described in the Medical procedure and EMI precautions manual. MRI scans should be performed only in a specified MR environment under specified conditions as described in the Reveal LINQ MRI Technical Manual.

Patient Assistant

Operation of the Patient Assistant near sources of electromagnetic interference, such as cellular phones, computer monitors, etc., may adversely affect the performance of this device.

Potential Complications

Potential complications include, but are not limited to, device rejection phenomena (including local tissue reaction), device migration, infection, and erosion through the skin.

Medtronic MyCareLink™ Patient Monitor, Medtronic CareLink™ Network, and CareLink™ Mobile Application

Intended Use

The Medtronic MyCareLink patient monitor and CareLink network are indicated for use in the transfer of patient data from some Medtronic implantable cardiac devices based on physician instructions and as described in the product manual. The CareLink mobile application is intended to provide current CareLink network customers access to CareLink network data via a mobile device for their convenience. The CareLink mobile application is not replacing the full workstation, but can be used to review patient data when a physician does not have access to a workstation. These products are not a substitute for appropriate medical attention in the event of an emergency and should only be used as directed by a physician. CareLink network availability and mobile device accessibility may be unavailable at times due to maintenance or updates, or due to coverage being unavailable in your area. Mobile device access to the Internet is required and subject to coverage availability. Standard text message rates apply.

Contraindications

There are no known contraindications.

Warnings and Precautions

The MyCareLink patient monitor must only be used for interrogating compatible Medtronic implantable devices.

See the device manual for detailed information regarding the implant procedure, indications, contraindications, warnings, precautions, and potential complications/adverse events. For further information, please call Medtronic at 1-800-328-2518 and/or consult the Medtronic website at medtronic.com.

Caution: Federal law (USA) restricts these devices to sale by or on the order of a physician.
DIAGNOSIS NEEDED. CHALLENGE ACCEPTED.

ACC/AHA/HRS & ESC Guidelines Recommend ICM in the Evaluation of Unexplained Syncope

CHOOSE REVEAL LINQ™ ICM FOR PATIENTS WITH SYMPTOMS > 30 DAYS APART

ICM Delivers Superior Diagnostic Yield for infrequent syncope compared to conventional testing

THE most effective diagnostic tool for infrequent, unexplained syncope

Unmatched detection accuracy

The most studied and validated ICM, with over 500 publications

Reveal LINQ™ ICM up to 3 years

20 YEARS OF ICM LEADERSHIP & INNOVATION

Medtronic
710 Medtronic Parkway
Minneapolis, MN 55432-5604
USA

Toll-free in USA: 800.633.8766
Worldwide: +1.763.514.4000

medtronic.com

UC201807848a EN ©2018 Medtronic.
Minneapolis, MN. All Rights Reserved.
Printed in USA. 06/2018

Medtronic and the Medtronic logo are trademarks of Medtronic.™ Third party brands are trademarks of their respective owners. All other brands are trademarks of a Medtronic company.